Farnesol

Farnesol: A Comprehensive Reference

1. Identity and Chemical Characterization

Chemical Names and Classification

Farnesol is a natural 15-carbon organic compound which is an acyclic sesquiterpene alcohol. Its systematic IUPAC name is 3,7,11-trimethyl-2,6,10-dodecatrien-1-ol, and it is also catalogued as trans,trans-3,7,11-trimethyl-2,6,10-dodecatrien-1-ol. Farnesol has a chemical formula of C₁₅H₂₅OH and a molecular mass of 222.372 g/mol. It carries the CAS registry number 4602-84-0 for the most common naturally occurring isomeric form.

Under standard conditions, it is a colorless liquid. It is hydrophobic, and thus insoluble in water, but miscible with oils. As the pyrophosphate ester, farnesol is a precursor to many terpenes and terpenoids. It is a constitutional isomer of Nerolidol. Multiple geometric isomers exist, with the trans,trans (all-E) configuration being the predominant form found in most plant essential oils and also produced endogenously by mammals.

Botanical and Natural Sources

Farnesol is a constituent of essential oil derived from various plants such as citronella, lemon grass, tuberose, cyclamen, rose, neroli, balsam, and musk. Farnesol, a colorless hydrophobic liquid with limited aqueous solubility but high miscibility in organic solvents such as ethanol, is renowned for its sweet floral fragrance. It is ubiquitously distributed in essential oils of diverse botanical species, notably Aniba rosaeodora, Abelmoschus moschatus, Cananga odorata, Acacia farnesiana, Myroxylon balsamum, Cymbopogon martinii, Polianthes tuberosa, Jasminum grandiflorum, and Citrus aurantium. It is also recoverable from fruits and food plants: it can be found in peaches, tomatoes, corn, chamomile, lemongrass, citronella, and others. In food processing contexts, farnesol has been used as a flavoring agent, and has been identified in more than 30 essential oils and other flora products used in food production — examples include apricot, citrus peel oils, grapefruit juice, strawberry jam, ginger, clove bud, hop oil, cardamom, thyme, beer, whiskey, basil, papaya, anise seed, and German chamomile.

In addition to plant systems, farnesol is present in animal and microbial organisms, where it plays crucial roles in intercellular signaling, quorum sensing modulation, and apoptosis regulation. Notably, it is a non-sterol isoprenoid (sesquiterpenoid alcohol) that can also be produced endogenously by the dephosphorylation of farnesyl pyrophosphate in the cholesterol biosynthesis pathway. Farnesol is also produced by yeast and is endogenously synthesized by mammalian cells as part of the mevalonate pathway; it is found in the human brain at concentrations of 110–290 pmol/g.

Nomenclature and Etymology

Farnesol was named (ca. 1900–1905) after the Farnese acacia tree (Vachellia farnesiana), since the flowers from the tree were the commercial source of the floral essence in which the chemical was identified. This particular acacia species, in turn, is named after Cardinal Odoardo Farnese (1573–1626) of the notable Italian Farnese family which (from 1550 through the 17th century) maintained some of the first private European botanical gardens in the Farnese Gardens in Rome. The plant itself was brought to the Farnese gardens from the Caribbean and Central America, where it originates.

Industrial Production and Commercial Forms

In industry, farnesol is produced from linalool. Farnesol is also primarily extracted from natural sources through physical separation techniques applied to plant materials rich in essential oils, such as those from citronella grass (Cymbopogon nardus) and rose flowers (Rosa damascena). Commercially, farnesol is available as a neat liquid (pure compound), in essential oil solutions and blends, as a component of perfumery concentrates, and as a cosmetic active ingredient. As a research chemical and dietary supplement ingredient, it is supplied dissolved in lipid carriers such as corn oil for oral administration, or formulated in ethanol-based preparations for topical and in vitro applications.

2. Historical and Traditional Use

Perfumery: The Principal Historical Application

Farnesol has been commercially produced from the flowers of the acacia tree for hundreds of years, and is still widely used in perfumery to emphasize sweet, floral scents and is also widely present in consumer products. It is used in perfumery to emphasize the odors of sweet, floral perfumes. It enhances perfume scent by acting as a co-solvent that regulates the volatility of the odorants. It is especially used in lilac and peony perfumes. Its aroma is described as "fresh, sweet, linden flower, floral, angelica, dry."

In perfumery, farnesol is used to anchor and enhance the components of a perfume. As a perfumery ingredient, the scent can be described as 'floral', 'green' and 'reminiscent of lily of the valley'. It is considered an excellent fixative for floral notes and is categorized as 'a base note with middle note effects'.

Traditional Medicinal and Ethnobotanical Use

Farnesol was not historically isolated as a pure compound in traditional medicine systems; rather, it was encountered as a constituent of the essential oils of aromatic plants used therapeutically. Historically, farnesol has been used in traditional herbal remedies, primarily for its pleasant aroma and potential health benefits. Ancient remedies often utilized farnesol-rich plant extracts to address respiratory ailments, skin conditions, and infections. Its soothing aroma and anti-inflammatory properties made it a popular ingredient in balms and ointments designed to relieve muscle pain and promote skin healing.

It must be emphasized that documented historical accounts of isolated farnesol use are scarce; the compound's presence in ethnomedicinal traditions is inferred from its constituent role in lemongrass, rose, chamomile, and acacia-based preparations that were used across Asian, Middle Eastern, and European traditions. There are no classical pharmacopeial monographs specifically for farnesol as a discrete medicinal ingredient.

Early Food and Flavoring Use

This substance has a wide application in the cosmetic and perfumery industries; it is used to improve sweet flower-based perfume scents and as an antibacterial cosmetic. Over time, farnesol has made its way into several different areas, and today it can be found functioning as a flavor enhancer for foods, as an additive to cigarettes, as a bactericide in hygienic products, and as a deodorizing agent.

3. Endogenous Biochemistry and Key Constituents

The Mevalonate (Isoprenoid) Pathway

Farnesyl pyrophosphate (FPP, doubly phosphorylated farnesol) is a key synthetic intermediate in the mevalonate pathway. It is the last common intermediate for the synthesis of cholesterol, coenzyme Q, and dolichol, and it is also used as the substrate for protein isoprenylation. Farnesol originates from three sources: (i) synthesis of FPP via the mevalonate pathway, followed by action by FPP phosphatase; (ii) degradation of prenylated proteins (although this has not been proved experimentally); or (iii) external sources, such as dietary or pharmaceutical.

Farnesol is produced from 5-carbon isoprene compounds in both plants and animals. Phosphate-activated derivatives of farnesol are the building blocks of possibly all acyclic sesquiterpenoids. These compounds are doubled to form 30-carbon squalene, which is the precursor for steroids in plants, animals, and fungi.

HMG-CoA Reductase Regulation

Farnesol is believed to be a non-sterol regulator for HMG-CoA reductase levels, and this means that farnesol could play an important role in regulating cholesterol levels. However, the precise role remains a subject of ongoing scientific investigation: HMG-CoA reductase is regulated by a complex multivalent feedback mechanism to ensure the synthesis of essential non-sterol metabolites continues, even in the presence of excess cholesterol. This regulation is accomplished by having HMG-CoA reductase activity sensitive to both sterol and non-sterol intermediates of the cholesterol biosynthetic pathway; however, the identity of the putative non-sterol intermediate is still uncertain.

Farnesol, in the form of FPP, is a product of this pathway, downstream of HMG-CoA; therefore endogenous FPP (and consequently farnesol) levels are also reduced by statins. In fact, some of the effects of statins can be reversed if farnesol is given, which indicates that farnesol is converted into FPP in vivo.

Nuclear Receptor Interactions

In some cell types the action of farnesol is mediated through nuclear receptors, including activation of farnesoid X receptor (FXR) and peroxisome proliferator-activated receptors (PPARs). Farnesol has a significant effect on epidermal keratinocyte differentiation and promotes growth arrest and differentiation through the activation of the PPARα signaling pathway.

Calcium Channel Modulation

Both cis,trans (plants) and all-trans (mammals) farnesol isomers are potent pharmacological antagonists of L- and N-type voltage-gated Ca²⁺ channels, channels implicated in cell growth and neurotransmission. The presence of farnesol in the human brain suggests that it is a signaling molecule potentially involved in regulating CNS calcium homeostasis, neurotransmission, and protection against neuronal calcium overload.

Metabolism: Glucuronidation

Research published in PMC has demonstrated that farnesol undergoes phase II metabolism via glucuronidation. Farnesol (trans,trans-3,7,11-trimethyl-2,6,10-dodecatrien-1-ol) is a sesquiterpene/isoprenoid originally discovered and isolated from plants, although it is now produced synthetically. Human liver, kidney, and intestinal microsomes have been shown to glucuronidate farnesol; it has been identified as a novel substrate for the UDP-glucuronosyltransferase enzymes UGT2B7 and UGT1A1, which are the same enzymes responsible for the metabolism of numerous drugs and endogenous compounds.

4. Mechanisms of Action

Apoptosis Induction and Cell Cycle Arrest

The isoprenoid alcohol farnesol is an effective inducer of cell cycle arrest and apoptosis in a variety of carcinoma cell types. In addition, farnesol has been reported to inhibit tumorigenesis in several animal models, suggesting that it functions as a chemopreventative and anti-tumor agent in vivo. A number of different biochemical and cellular processes have been implicated in the growth-inhibitory and apoptosis-inducing effects of farnesol. These include regulation of HMG-CoA reductase and CTP:phosphocholine cytidylyltransferase α (CCTα), the rate-limiting enzymes in the mevalonate pathway and phosphatidylcholine biosynthesis, respectively, and the generation of reactive oxygen species.

Induction of endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR) provides a major mechanism by which farnesol inhibits cell proliferation and promotes apoptosis in certain cell types. The ER stress response was found to depend on the activation of the MEK-ERK signaling pathway.

NF-κB and Inflammatory Mediator Modulation

To exert its anti-inflammatory/anti-oncogenic effects, farnesol can modulate Ras protein and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation to downregulate the expression of various inflammatory mediators such as cyclooxygenase-2, inducible nitric oxide synthase, tumor necrosis factor alpha, and interleukin-6.

Reactive Oxygen Species (ROS) Generation

Increased production of ROS creates oxidative stress in cancer cells, which ultimately results in apoptosis. Elevated levels of ROS induce the activation of the mitochondria-dependent pathway of apoptosis. Farnesol was previously reported to induce ROS production in leukemia MOLT-4 cells, which led to a decrease in cell viability. It is important to note that the role of ROS in farnesol's effects is context-dependent: farnesol has also been demonstrated to induce ROS and apoptosis in yeast; however, additional studies are required to establish whether ROS plays a role in the induction of apoptosis in mammalian cells.

Quorum Sensing and Microbial Signaling

Apart from being produced by various plants, farnesol has also been excreted as a quorum sensing molecule by the fungus Candida albicans. It also acts as a virulence factor, with mutants producing less and more farnesol becoming less and more infectious respectively. This morphological autoregulatory molecule exerts its antifungal effect primarily through inhibition of the Ras1-cAMP pathway and cAMP signaling via the direct inhibition of Cyr1 activity.

PARIS Farnesylation and Neuroprotection

In the brains of people with Parkinson's disease, a buildup of PARIS (Parkin-interacting substrate) slows down the manufacture of the protective protein PGC-1α. The protein shields brain cells from damaging reactive oxygen molecules that accumulate in the brain. Without PGC-1α, dopamine neurons die off, leading to the cognitive and physical changes associated with Parkinson's disease. Farnesol enhances the amounts of farnesylated PARIS and PGC-1α, preventing dopaminergic neuronal loss in Parkinson's disease models.

5. Scientific Evidence by Area of Use

5.1 Oncology: Anticancer and Chemopreventive Activity

Evidence level: Predominantly preclinical (in vitro and animal models); no published randomized controlled trials in humans.

In numerous tumor cell lines, farnesol can modulate various tumorigenic proteins and/or modulates diverse signal transduction cascades. It can also induce apoptosis and downregulate cell proliferation, angiogenesis, and cell survival. Research reviewed in a 2018 PMC publication identified activity across multiple cancer types including leukemia, cervical cancer, lung cancer, and colon cancer cell lines.

Farnesol, found in the essential oils of various plants, has been shown to possess antioxidant, anti-inflammatory, and anticancer properties. However, the anticancer effect of farnesol against colorectal carcinoma and osteosarcoma has not yet been adequately elucidated. A 2024 cell line study addressed this gap using human osteosarcoma (Saos-2) and colorectal carcinoma (HCT-116) cell lines: cells were treated with concentrations ranging from 10 to 120 µM/ml of farnesol for 24 hours. Farnesol exhibited cytotoxicity against Saos-2 and HCT-116 cells by inducing ROS-mediated apoptosis.

A study published in Neoplasia (2008) investigated the effects of farnesol on oral squamous cell carcinoma (OSCC). This study demonstrates that farnesol significantly inhibits the proliferation of OSCCs and promotes apoptosis in vitro through both the intrinsic and extrinsic apoptotic signaling pathways. Cell proliferation, apoptosis, mitochondrial degradation, and survivin and caspase expressions were examined. In addition, global protein expression profiles were analyzed using proteomic analysis. Results demonstrated significant decrease in proliferation and increase in apoptosis in cells exposed to farnesol and C. albicans culture media.

In prostate cancer research, treatment with farnesol showed reduced levels of antiapoptotic protein Bcl-2 and rise in apoptotic proteins Bax, caspase 3 and caspase 9 as compared to the control group.

Studies have revealed farnesol to be efficacious as a potential anti-cancer agent as it can exert cytotoxic effects against various neoplastic cell lines and can significantly inhibit tumor growth in vivo. Critically, all available evidence as of the current literature remains preclinical. These findings support the clinical development of farnesol as a potential pharmacological agent in clinical studies, but no human clinical trials have been published to date.

5.2 Anti-Inflammatory Activity

Evidence level: Animal (in vivo) and in vitro; no human clinical trials.

Overall, several studies have demonstrated the potential pro/anti-inflammatory and anti-cancer effects of farnesol in various diseases and cancers. Although farnesol displayed a more pro-inflammatory effect under in vitro settings, in vivo findings showed that it is likely to act in an anti-inflammatory fashion in various chronic inflammation-induced diseases such as asthma. This could be attributed to inflammation being a process that is dependent on the extracellular milieu, where various types of immune cells also contribute to a pro- or anti-inflammatory environment.

In a mouse model of ovalbumin-sensitized and -challenged asthmatic mice, farnesol supplementation significantly restored the cytokine secretion ability of peritoneal macrophages that was suppressed as a result of OVA sensitization and challenge and slightly decreased TNF-α/IL-10 cytokine secretion ratios. Farnesol supplementation slightly decreased IL-4 but significantly increased IL-2 levels secreted by the splenocytes in the presence of OVA, implying that farnesol might have a systemic antiallergic effect on allergic asthmatic mice. Farnesol supplementation significantly increased IL-10 levels secreted by the splenocytes in the presence of OVA, suggesting that farnesol might have an anti-inflammatory potential to allergic asthmatic mice. Overall, the results suggest that farnesol supplementation may be beneficial to improve the Th2-skewed allergic asthmatic inflammation.

In a rat model of cigarette smoke-induced lung injury: farnesol was administered by gavage (50 and 100 mg/kg body weight in corn oil) once daily for 7 days. On day 7, lung injuries were induced by intratracheal instillation of aqueous cigarette smoke extract. Prophylactic treatment with farnesol significantly showed lung protection by lowering the levels of LDH, total cell count, total protein, and MDA in bronchoalveolar lavage fluid. Farnesol maintained the phospholipid content of bronchoalveolar lavage fluid in a positive manner.

5.3 Antimicrobial and Antifungal Activity

Evidence level: In vitro and some animal models; no published human clinical trials for therapeutic use.

Its role as a quorum sensing molecule and as a virulence factor of Candida albicans has been well described. Studies revealed that farnesol affects the growth of a number of bacteria and fungi, pointing to a potential role as an antimicrobial agent.

Research in Annals of Clinical Microbiology and Antimicrobials evaluated farnesol's activity against Paracoccidioides brasiliensis. Concentrations of this isoprenoid ranging from 25 to 300 µM strongly inhibited P. brasiliensis growth. The minimum inhibitory concentration (MIC) of farnesol for P. brasiliensis was estimated at 25 µM, while the minimum lethal concentration (MLC) is around 30 µM. When employing levels which don't compromise cell viability (5 to 15 µM), it was shown that farnesol also affected the morphogenesis of this fungus. Approximately 60% inhibition in hyphal development was observed following P. brasiliensis yeast cell treatment with 15 µM of farnesol for 48 hours.

Regarding vulvovaginal candidiasis, a 2023 study in BMC Microbiology found: farnesol was effective in reducing the adhesion of C. albicans to vaginal epithelial cells at low concentrations (50 µmol/L). Only low concentrations (≤ 50 µmol/L) of farnesol did not affect the morphology and viability of the VK2 cells.

In studies of C. albicans biofilm and morphogenesis: exogenous farnesol used with C. albicans downregulates hyphae morphogenesis through cell wall changes and secreted aspartyl proteinase (Sap2, Saps4–6) mRNA expression decrease. Overall results suggest the possible use of farnesol as an antifungal agent.

A first systematic review on farnesol pharmacology found that 51.32% of reviewed articles investigated the antimicrobial effect of farnesol, making this the single most-researched pharmacological area for this compound.

5.4 Neuroprotection: Parkinson's Disease and Neuroinflammation

Evidence level: Preclinical animal models and in vitro; published in Science Translational Medicine (2021) but no human clinical trials yet completed.

Johns Hopkins Medicine researchers say they have added to evidence that the compound farnesol, found naturally in herbs, and berries and other fruits, prevents and reverses brain damage linked to Parkinson's disease in mouse studies. The compound can prevent the loss of neurons that produce dopamine in the brains of mice by deactivating PARIS, a key protein involved in the disease's progression.

The researchers' experiments showed that farnesol both significantly prevented the loss of dopamine neurons and reversed behavioral deficits in mice, indicating its promise as a potential drug treatment to prevent Parkinson's disease. This work was published in Science Translational Medicine. Though more research is needed, the research team hopes farnesol can someday be used to create treatments that prevent or reverse brain damage caused by Parkinson's disease.

Farnesol is pharmacologically active and has demonstrated protective effects on multiple cellular signaling pathways, all of which are involved in the pathogenesis of neuroinflammatory conditions.

Separately, a 2021 study in PMC evaluated farnesol against experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis: researchers sought to determine whether farnesol treatment would result in protection against murine EAE. They compared disease progression and severity in C57BL/6 mice treated orally with 100 mg/kg/day farnesol solubilized in corn oil to corn-oil treated and untreated EAE mice. Farnesol significantly delayed the onset of EAE (by approximately 2 days) and dramatically decreased disease severity (approximately 80%) compared to controls. Disease protection by farnesol was associated with a significant reduction in spinal cord infiltration by monocytes-macrophages, dendritic cells, CD4+ T cells, and a significant gut microbiota composition change, including a decrease in the Firmicutes:Bacteroidetes ratio. All of this evidence remains animal-model-based.

5.5 Musculoskeletal and Aging-Related Muscle Function

Evidence level: Preclinical (animal models); no human clinical trials.

A 2023 study published in PubMed demonstrated that farnesol administration enhanced oxidative muscle capacity and muscle strength, leading to metabolic rejuvenation in aged mice. Farnesol treatment also accelerated the recovery of muscle injury associated with enhanced muscle stem cell function. The protein expression of PARIS (Zfp746), a transcriptional repressor of PGC-1α, was elevated in aged muscles, likely contributing to PGC-1α reduction. The beneficial effect of farnesol on aged muscle was mediated through enhanced PARIS farnesylation, thereby relieving PARIS-mediated PGC-1α suppression. These results are intriguing but remain in the animal-model stage.

5.6 Respiratory / Pulmonary Protection

Evidence level: Animal (rodent) models only.

Beyond the cigarette smoke model described above, farnesol is found to alleviate massive inflammation, oxidative stress, and lung injury induced by the intratracheal instillation of cigarette smoke extract in rats. The protective effect of farnesol against cigarette smoke-induced lung injury and oxidative stress may relate to inhibition of cancer initiation and result in a reduced probability of lung cancer.

5.7 Gastrointestinal Activity

Evidence level: Animal (rodent) studies; no human trials.

In view of the results presented in one rodent study, the antidiarrheal activity of farnesol occurs through anticholinergic, anti-inflammatory and anti-secretory action, making farnesol a potential candidate for the development of a new drug to treat diarrheal diseases. This research was conducted at Brazilian federal university laboratories and published in the European Journal of Pharmacology (2020).

5.8 Overall Systematic Review Findings

Methodological biases have been observed both in pre-clinical studies with non-human animals and in clinical trials, mainly in group allocation and blinding. A 2019 descriptive systematic review was the first study developed to compile the studies concerning the pharmacological and toxicological effects of farnesol. This study concludes that farnesol possesses different pharmacological and toxicological features, which permit its use as an active or a coadjuvant drug.

6. Body Systems Associated with Farnesol

• Oncology / Cell biology: Pro-apoptotic activity in multiple cancer cell lines; inhibition of angiogenesis and cell proliferation.
• Immune system / Inflammation: Modulation of NF-κB, TNF-α, IL-6, COX-2, and iNOS; context-dependent pro- and anti-inflammatory effects.
• Microbial defense: Antifungal activity against C. albicans and related fungi; antibacterial properties against multiple species.
• Central nervous system: The pharmacological properties of farnesol encompass quorum sensing and microbial biofilm inhibition, neuroinflammatory protection, and modulation of intracellular calcium (Ca²⁺) signaling pathways.
• Cardiovascular / Lipid metabolism: Interaction with the mevalonate pathway and regulation of HMG-CoA reductase activity.
• Musculoskeletal: Enhancement of muscle oxidative capacity and stem cell function in aged animals via PARIS-PGC-1α axis.
• Respiratory: Protective effect against cigarette smoke-induced lung inflammation and oxidative stress in rodents.
• Gastrointestinal: Antidiarrheal activity via anticholinergic and anti-secretory mechanisms in rodents.
• Skin: Keratinocyte differentiation via PPARα activation; antimicrobial/deodorizing properties in cosmetic use.

7. Dosage Forms and Reported Dosages

Farnesol has not been approved as a pharmaceutical drug in any major regulatory jurisdiction. It is not yet approved for medical use. The following dosages are those reported in published preclinical research and are presented only as documented in those sources; they do not represent established human dosage recommendations.

• Rodent oral gavage (lung protection model): Farnesol was administered by gavage at 50 and 100 mg/kg body weight in corn oil, once daily for 7 days.
• Mouse oral dietary model (EAE/multiple sclerosis model): C57BL/6 mice were treated orally with 100 mg/kg/day farnesol solubilized in corn oil.
• In vitro cytotoxic studies (osteosarcoma/colorectal cells): Cells were treated with 10, 20, 40, 60, 80, and 100 µM/ml and 20, 40, 60, 80, 100, and 120 µM/ml of farnesol for 24 hours, respectively.
• In vitro antifungal (vaginal epithelial cell study): Farnesol was effective in reducing the adhesion of C. albicans to vaginal epithelial cells at low concentrations (50 µmol/L).
• In vitro antifungal (P. brasiliensis): Concentrations ranging from 25 to 300 µM strongly inhibited P. brasiliensis growth. The MIC was estimated at 25 µM and the MLC at around 30 µM.

8. Safety Considerations and Regulatory Status

Skin Sensitization

The most thoroughly characterized safety concern for farnesol is its capacity to cause skin sensitization. The Research Institute for Fragrance Materials (RIFM) has completed an official safety assessment for this ingredient and concluded that farnesol is a weak skin sensitizer. These findings have been approved by The Expert Panel for Fragrance Safety, an independent expert advisory board.

It has been identified by European Union scientific bodies as a potential skin sensitizer. This means that farnesol has the potential to cause a skin reaction (such as red, bumpy, or itchy skin).

European Union Regulatory Requirements

The European Cosmetics Regulation requires manufacturers of cosmetics and personal care products to indicate the presence of certain "allergenic" substances in the list of ingredients if they are present above certain levels in the product. The presence of farnesol must be indicated in the list of ingredients when its concentration exceeds 0.001% in leave-on skin products and 0.01% in products that are rinsed off the skin.

Farnesol is included in the EU 26 list of fragrances that must be labeled separately on the product packaging because of its potential as an allergen.

IFRA Standards

The International Fragrance Association (IFRA) has established a standard that restricts the use of farnesol in fragrances because of this potential for sensitization. IFRA has set a standard for acceptable concentrations of farnesol that can be used in a variety of consumer products. The IFRA has classified farnesol in subcategory 2, which contains products with an allergenic potential that is observed with less frequency but still in a significantly large number of subjects.

Photoirritation and Photoallergenicity

The photoirritation/photoallergenicity endpoints were evaluated based on data and ultraviolet/visible (UV/Vis) spectra; farnesol is not expected to be photoirritating or photoallergenic.

Drug Interaction Considerations: Statin Therapy

Given farnesol's role as a mevalonate pathway intermediate, an interaction with statin-class drugs is pharmacologically plausible. Farnesol, in the form of FPP, is a product of this pathway downstream of HMG-CoA; therefore endogenous FPP (and consequently farnesol) levels are also reduced by statins. Some of the effects of statins can be reversed if farnesol is given, which indicates that farnesol is converted into FPP in vivo. The clinical significance of exogenous farnesol supplementation in statin-treated patients has not been evaluated in human trials.

Drug Metabolism Interactions: UGT Enzyme Substrate

Because farnesol has been demonstrated to be a substrate for UGT2B7 and UGT1A1 in human liver, kidney, and intestine in vitro, it shares these metabolic enzymes with a number of commonly used pharmaceuticals. Theoretical drug-drug interactions at these enzymes are possible, though no clinical interaction studies have been conducted.

General Toxicological Profile

This substance possesses different pharmacological and toxicological features, which permit its use as an active or a coadjuvant drug. In the EAE mouse model, no overt toxicity was reported at oral doses of 100 mg/kg/day. In the lung-protection rat model, doses of up to 100 mg/kg/day by gavage were used without reported adverse effects. Context-dependent pro-inflammatory effects have been observed in certain in vitro settings, as discussed above under the anti-inflammatory section.

References

• Aggarwal BB et al. "Potential Anti-Inflammatory and Anti-Cancer Properties of Farnesol." PMC / Molecules, 2018.
• Braun P et al. "Molecular Mechanisms involved in Farnesol-Induced Apoptosis." PMC, 2010.
• Jabra-Rizk MA et al. "Farnesol-Induced Apoptosis in Candida albicans." PMC, 2009.
• Scheper MA et al. "Farnesol, a Fungal Quorum-Sensing Molecule Triggers Apoptosis in Human Oral Squamous Carcinoma Cells." PMC / Neoplasia, 2008.
• Kischkel B et al. "Antimicrobial effect of farnesol, a Candida albicans quorum sensing molecule, on Paracoccidioides brasiliensis." PMC / Annals of Clinical Microbiology and Antimicrobials, 2009.
• Ramage G et al. "Farnesol Triggers Candida Albicans Morphological Changes by Downregulating the Expression of Different Secreted Aspartyl Proteinase Genes." PMC, 2012.
• Xu M et al. "The fungal quorum-sensing molecule, farnesol, regulates the immune response of vaginal epithelial cells against Candida albicans." PMC / BMC Microbiology, 2023.
• "Anticancer Potential of Farnesol Against Human Osteosarcoma Saos-2 Cells and Human Colorectal Carcinoma HCT-116 Cells." PMC, 2024.
• Chen CY et al. "Farnesol, a Sesquiterpene Alcohol in Herbal Plants, Exerts Anti-Inflammatory and Antiallergic Effects on Ovalbumin-Sensitized and -Challenged Asthmatic Mice." PMC / Evidence-Based Complementary and Alternative Medicine, 2015.
• Sareen R et al. "Farnesol ameliorates massive inflammation, oxidative stress and lung injury induced by intratracheal instillation of cigarette smoke extract in rats." PubMed, 2008.
• Doyle S et al. "Farnesol induces protection against murine CNS inflammatory demyelination and modifies gut microbiome." PMC, 2021.
• Jo A et al. "PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease." Science Translational Medicine, 2021.
• "Farnesol prevents aging-related muscle weakness in mice through enhanced farnesylation of Parkin-interacting substrate." PubMed, 2023.
• Da Costa DS et al. "Antidiarrheal activity of farnesol in rodents: Pharmacological actions and molecular docking." PubMed / European Journal of Pharmacology, 2020.
• "Toxicological and pharmacologic effects of farnesol (C15H26O): A descriptive systematic review." PubMed / Food and Chemical Toxicology, 2019.
• "Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1." PMC, 2005.
• "Farnesol, the farnesol pathway, and the immune-gut-brain axis." Frontiers in Pharmacology, 2026.
• Wikipedia: Farnesol (for etymology and physical properties).
• Johns Hopkins Medicine News: "Fruit Compound May Have Potential to Prevent and Treat Parkinson's Disease, Mouse Study Suggests." 2021.
• "Waiting for PARIS-A Biological Target in Search of a Drug." PubMed, 2021.
• The Fragrance Conservatory: Farnesol — RIFM safety assessment summary.
• European Commission SCCP: Fragrances — Farnesol restriction assessment (EU Scientific Committee on Consumer Products).